Regeneron Ventures Research
Investment Thesis
Regeneron Ventures is the independent corporate venture capital arm of Regeneron Pharmaceuticals, launched in April 2024 with a $500 million commitment. The firm's stated mission is to "invest wisely to help build and grow companies that become great by improving health." It is explicitly agnostic to therapeutic area, technology, and stage of development, choosing instead to underwrite on the quality of the people, the science, and the data behind each opportunity. The fund operates independently of Regeneron Pharmaceuticals' internal R&D priorities and is not a strategic pipeline-feeder vehicle in the traditional pharma-CVC sense; its two managing partners describe a philosophy that treats each company as idiosyncratic and encourages founders to follow their own path rather than conform to a house model.
Sector Focus
The fund's mandate is healthcare broadly, with a clear skew toward:
- Biotechnology and biopharmaceutical drug discovery and development
- Medical devices and diagnostic tools
- Enabling technologies and platforms (synthetic biology, AI-driven discovery, antibody and RNA platforms)
- Cell and gene therapy
Based on observed activity, the firm has been especially active in molecular glue degraders, programmable mRNA therapeutics, RNAi/siRNA platforms, AI-driven drug discovery, antibody discovery platforms, and thymus-targeted immune tolerance approaches.
Stage Focus
Regeneron Ventures states it is stage-agnostic, and its observed portfolio bears this out. Tracked activity shows investments concentrated in Series A through Series C, with the heaviest cadence at Series A and Series B, alongside occasional larger, later Series C checks into more capital-intensive clinical-stage programs.
Check Size
The firm does not publish a fixed check-size range. Regeneron Pharmaceuticals commits $100 million annually for five years as the fund's sole limited partner, and the firm has participated in syndicated rounds ranging from roughly $55 million (Series A) to over $150 million (Series B), typically as one of several co-investors rather than disclosing its individual check size.
Lead Tendency
Regeneron Ventures most often participates alongside other institutional biotech investors rather than acting as sole lead, but it has co-led rounds on multiple occasions (e.g., Infinimmune's Series A, Think Bioscience's Series A), indicating a willingness to take an active, structuring role when conviction is high.
Recent Activity
The fund has been steadily active since its 2024 launch, with roughly 7 investments in 2025 and continued deployment into 2026:
- Strand Therapeutics — $153M Series B (August 2025) for programmable mRNA cancer therapeutics
- Zag Bio — $80M launch financing (October 2025) for thymus-targeted autoimmune medicines
- Iambic Therapeutics — $100M+ oversubscribed round (November 2025) for AI-discovered therapeutics
- Triana Biomedicines — $120M oversubscribed Series B (December 2025) for molecular glue degraders
- Think Bioscience — $55M oversubscribed Series A (January 2026), co-led, for synthetic biology drug discovery
- Coultreon Biopharma — $125M Series A (April 2026) for an immunology pipeline
- Infinimmune — $75M Series A (August 2026), co-led with Playground Global, for human-derived antibody discovery
Portfolio Highlights
Notable portfolio companies include ArsenalBio (programmable cell therapy, $325M Series C in 2024) and City Therapeutics (RNAi/siRNA therapeutics, follow-on financing in 2026), alongside the recent 2025-2026 cohort above. The portfolio skews toward well-capitalized, platform-driven biotech companies with strong existing syndicates (Bessemer, Ascenta Capital, RA Capital, Atlas Venture, Lightspeed, Sofinnova, Polaris Partners, Kinnevik).
Team
- Jay S. Markowitz, M.D., Managing Partner & Co-Founder — Previously a senior partner at Arch Venture Partners, where he founded three companies. Worked at Regeneron from 2017 to 2020, and earlier at T. Rowe Price Associates and Capital World Investors.
- Michael Aberman, M.D., Managing Partner & Co-Founder — Previously CEO of XenImmune Therapeutics and Quentis Therapeutics. Spent seven years at Regeneron, including as head of investor relations and strategy.
Decision Process
Investment strategy is led jointly by the two managing partners, both former Regeneron executives, with Regeneron Pharmaceuticals as the fund's sole limited partner. Decisions are described as grounded in "the quality of the people, science, and data" rather than a rigid scoring framework.
Founder Preferences
The firm explicitly avoids forcing portfolio companies into a single mold, stating that "companies are idiosyncratic, if not unique, and should follow their own path." This suggests a preference for scientifically differentiated founding teams with strong technical and clinical credibility over founders optimizing purely for a specific playbook.
Geographic Focus
The fund's disclosed activity is concentrated in the United States, spanning the Boston/Cambridge biotech cluster (Strand Therapeutics, Zag Bio, Triana Biomedicines), the Bay Area (Infinimmune, ArsenalBio), and San Diego (Iambic Therapeutics), with Regeneron Ventures itself associated with a Greenwich, CT address.